# Albuminurie en cardiovasculair risico: gemiste kans in de 2025 ESC/EAS-dyslipidemierichtlijnen

*geplaatst 2026-01-02 · Cholesterol · Atherosclerosis · doi https://www.atherosclerosis-journal.com/article/S0021-9150(25)01531-X/fulltext · https://hartvaat.nl/2026/01/02/albuminurie-en-cardiovasculair-risico-gemiste-kans-in-de-2025-esc-eas-dyslipidem/*

De Spaanse nefrologievereniging en arteriosclerosevereniging verwelkomen de 2025 ESC/EAS-update maar signaleren dat albuminurie als cardiovasculaire risicoverhoger onvoldoende is meegenomen in de richtlijn.

## English: Albuminuria and cardiovascular risk: A missed opportunity in the 2025 focused update of the ESC/EAS dyslipidaemia guidelines

The Spanish Societies of Nephrology and Arteriosclerosis welcome the 2025 ESC/EAS dyslipidaemia guidelines update but identify albuminuria as an insufficiently incorporated cardiovascular risk enhancer. The commentary advocates for broader integration of kidney markers in lipid management.

## Abstract (original, from the publication)

The Spanish Societies of Nephrology (Sociedad Española de Nefrología, SEN) and Arteriosclerosis (Sociedad Española de Arteriosclerosis, SEA) welcome the new 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias [1,2]. This Focused Update is aimed to be aligned with the 2021 ESC Guidelines on cardiovascular disease (CVD) prevention [3] and endorses the use of risk scores such as SCORE2 and SCORE2-OP (instead of the previous SCORE algorithm) to estimate the risk of myocardial infarction, ischaemic stroke, or fatal atherosclerotic CV event over the next 10 years in persons without known CVD aged between 40 and 89 years (2025 Focused update Recommendations) [1,2].

Auteurs: Carlos Guijarro, Alberto Ortiz

---
Bron: Atherosclerosis, https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01531-X/fulltext. Bijgewerkt 2026-07-03T13:24:59Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.